Zheshang Bank: Writing a major article on science and technology finance to care for the whole picture of biomedicine

This year, for the first time, the new quality of productivity was written into the government work report. In the environment of continuous narrowing of interest rate spreads and fluctuating capital markets, commercial banks represented by Zheshang Bank have further increased their financial support for science and technology enterprises, and the initial results of developing new quality productivity are emerging.

On May 11, led by the United Front Work Department of the Zhejiang Provincial Party Committee and the Provincial Department of Science and Technology, the launching ceremony of the province's united front to help innovation and deepen the meritorious action and the new knowledge and new quality roundtable (biomedical session) were held in Hangzhou, bringing together a number of leaders and experts from government departments, scientific research institutes, financial institutions and enterprises, and Lu Jianqiang, director of the Financial Services Committee of the General Association of Zhejiang Entrepreneurs, Secretary of the Party Committee and Chairman of Zheshang Bank, was invited to attend and speak as a representative of the financial industry.

Lu Jianqiang pointed out that the Central Financial Work Conference put science and technology finance in the first place of the "five major articles", and endowed science and technology finance with a strong historical mission and responsibility. Over the years, Zheshang Bank has actively shouldered the mission of provincial financial enterprises and national joint-stock banks with the service concept of "good finance", continuously improved the financial service system of characteristic science and technology, optimized financial supply, practiced the financial advisory system, and helped the innovation and development of biomedical enterprises.

According to reports, as of the end of April, the bank had served more than 15,000 science and technology enterprises, with a financing balance of more than 210 billion yuan, including more than 1,300 biomedical enterprises.

Based on kindness, we will deeply cultivate the 100 billion track of biomedicine

Biomedicine is the strategic commanding heights of the new round of global scientific and technological revolution and industrial revolution, and it is also an important component of the "315" scientific and technological innovation system in Zhejiang Province, and Zheshang Bank has been deeply engaged in this field for nearly ten years.

In 2016, the bank launched the country's first "Talent Bank" financial service brand with high-level talents as the precise service object, gathering the power of talents to help scientific and technological innovation. In 2021, the bank integrated and iterated technology financial services, further expanded the scope of services, and launched the "Spark Plan" special service action for science and technology finance, providing "full-cycle, full-chain, and all-round" comprehensive financial services to scientific and technological innovation enterprises represented by biomedical enterprises.

Zhejiang Huayi Health Industry Development Co., Ltd. (hereinafter referred to as "Huayi Health") is one of the epitomes. Zhejiang Huayi Health Industry Development Co., Ltd., located in Tonglu, is a medical enterprise focusing on tumor treatment technology, with high R&D costs and large capital needs, and the company was once in trouble.

"In the most difficult time, Zheshang Bank provided us with a credit loan in a timely manner with a talent certificate and a business plan, which solved our urgent needs." Yang Guanghua, founder and chief scientist of Huayi Health, introduced.

It is understood that the Hangzhou branch of Zheshang Bank took the initiative to contact Yang Guanghua's company, and after due diligence and fast process, issued the first credit loan of 5 million yuan to Huayi Health. In the same year, Yang Guanghua led the team to invent the "nano gun" malignant solid tumor treatment technology, which made a breakthrough, and the world's first clinical trial for advanced liver cancer was successfully conducted in Zhejiang Provincial People's Hospital, which is of great social significance.

"Shan Ben Finance" is an important development concept of Zheshang Bank, and it is also the core purpose of the bank to support pharmaceutical enterprises. Through a franchised organizational system, exclusive products and services, a professional team, exclusive risk policies, special business policies and special information systems, Zheshang Bank tailors for the biomedical industry to help enterprises better respond to market challenges, assume social responsibilities, and actively respond to public expectations.

100 billion track, eight years of hard work. At present, Zheshang Bank has formed a service system of 10 major financial service scenarios and 16 major technology and financial products around the whole life cycle of biomedical enterprises, empowering talent cultivation and technological innovation in the biomedical industry with a comprehensive picture plan, and accompanying biomedical enterprises to grow together.

Living water drip irrigation, deciphering the financing problems of start-ups

Biomedical enterprises in the start-up stage need precise drip irrigation of "financial living water". The high-risk, high-growth development model, asset-light, lack of collateral, lack of guarantees, difficult evaluation and other financing characteristics all mean that biopharmaceutical enterprises need more professional and diversified financial support.

Faced with the problem of "drip irrigation", Zheshang Bank solved the problem with "talent bank". By focusing on the core asset of "human capital", the bank innovatively launched the country's first "talent bank" service brand and talent loan product for high-level talents, and directly provided credit lines according to the level and qualifications of talents, so as to solve the financing difficulties in the early stage of biopharmaceutical enterprises. As of the end of April, Zheshang Bank had served more than 1,300 biomedical enterprises through the "Talent Bank" model, which has become the bank's business card in the field of science and technology financial innovation.

"Multi-party sharing" is another solution found by Zheshang Bank. In order to help the development of biomedical enterprises in the start-up and growth stages, Zheshang Bank has innovatively launched the "Science and Technology Innovation Co-sharing Loan", which solves the financing problems of biomedical start-up enterprises and provides efficient and convenient credit loan financing services for "asset-light" science and technology enterprises by introducing government compensation funds, guarantee companies, insurance companies and other cooperative institutions.

The case of Suzhou Shenxi Xingsheng Biopharmaceutical Co., Ltd. (hereinafter referred to as "Shenxi Biopharmaceutical") verifies the efficiency of the "drip irrigation" solution of credit. Shenxi Biotech has subsidiaries in the United States and China, and its founder, Professor Gong Chen, is one of the first pioneers in the world to use endogenous astrocytes in the brain to directly transtype into functional neurons in adult mammals.

According to Dr. Sheng Jian, CEO of Shenxi Biotech, Shenxi Biotech's gene therapy product pipeline covers a variety of common diseases and rare diseases, with large investment in basic research in the early stage and a long R&D output cycle, which requires a large amount of financial support.

Under the influence of the epidemic, the company's cash flow is under pressure. In the face of Shenxi Biotech's financing needs, Zheshang Bank responded positively, and its Suzhou branch became the first lending bank. Dr. Sheng Jian said, "Zheshang Bank responds quickly to the needs of our enterprises, from data submission to quota approval, which is very efficient. ”

Consultant escort, the whole chain of care for the growth of the industry

From scientific and technological research and development, to the transformation of achievements, and then to the benefit output, Zheshang Bank provides full-cycle, full-chain and all-round financial support for biomedical enterprises. In 2022, the bank innovatively proposed a new model of integrated financial consulting services for science and technology enterprises, which is customer-centric, and through the "1" of financial advisory, it links the "N" of guarantees, brokers, insurance, venture capital, funds, law firms, business incubation, etc., to provide comprehensive financial ecological services across financial licenses for biomedical enterprises and meet the all-round financial needs of enterprises.

Zhejiang Tongyuankang Pharmaceutical Co., Ltd. (hereinafter referred to as "Tongyuankang") is a clinical-stage biopharmaceutical company dedicated to the discovery and development of differentiated targeted cancer therapies.

Accompanying the growth of the enterprise for many years, the financial consultant of Zheshang Bank has visited the enterprise several times to understand the core financial demands of the enterprise at different stages. After learning that the enterprise needs the support of investment institutions, Zheshang Bank and a number of financial institutions such as securities and funds have made joint efforts to help enterprises "matchmaking" in the capital market and help enterprises complete multiple rounds of financing in the process of starting a business. At present, Tongyuankang has obtained the notice of approval from the US FDA to carry out clinical trials.

Represented by supporting the biomedical industry, Zheshang Bank has delivered a brilliant answer sheet for new quality productivity of financial services and scientific and technological innovation. The relevant person in charge of Zheshang Bank said that up to now, the bank has served more than 15,000 science and technology enterprises, with a financing balance of more than 210 billion yuan.

It is reported that in the future, Zheshang Bank will anchor science and technology enterprises, focus on industrial upgrading, continuously improve the service system, continue to optimize financial supply, and fully empower the development of new productive forces.